Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
131. |
ECCT/16/08/01 | A5349/TBTC S31 A5349/TBTC S31 “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial” |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
132. |
ECCT/16/08/02 | Zeenk study Zeenk Acceptability Study |
Principal Investigator(s) 1. Margaret Oluka 2. David Kimutai 3. Caren Emadu Site(s) in Kenya 1. Mbagathi District Hospital (Nairobi City county) 2. Mama Lucy Kibaki Hospital (Nairobi City county) |
View |
133. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
View |
134. |
ECCT/16/09/02 | Monitoring Pre-Exposure Prophylaxis for Young Adult Women ( (MPYA) Next generation real-time monitoring for PrEP adherence in young adult women. |
Principal Investigator(s) 1. Prof. Elizabeth Anne Bukusi Bukusi 2. Dr. Stella Njuguna Njuguna Site(s) in Kenya 1. KISUMU SITE (Kisumu county) |
View |
135. |
ECCT/16/09/03 | Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. |
Principal Investigator(s) 1. Dr.Pauline NM Mwinzi Site(s) in Kenya KEMRI CGHR |
View |